BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180119
DTEND;VALUE=DATE:20180221
DTSTAMP:20260729T184021
CREATED:20180119T214721Z
LAST-MODIFIED:20180119T215022Z
UID:19620-1516320000-1519171199@ces.b2sg.org
SUMMARY:Intern - Molecular Oncology
DESCRIPTION:Start Date: Summer 2018  \nLength of Assignment: 12 weeks  \nThe mission of the Molecular Oncology department is to bring lasting benefit and cures to cancer patients through innovative scientific discoveries and medicines.  \n\nWe will transform cancer care by taking a science-driven approach to drug discovery and development to achieve enduring clinical benefit.\nGuided by a deep understanding of the unique molecular features associated with each patient’s disease\, we will identify and understand pathways that drive cancer and establish the therapeutic potential of individual targets.\nBy combining laboratory and clinical investigation\, we will design strategies and medicines that target tumor cells\, drug resistance\, and the tumor microenvironment to achieve dramatic\, lasting\, benefit for cancer patients.\n\nPosition 1  \nThis intern will work with a postdoctoral fellow to investigate the impact of a kinase on the interaction between CD8 T cells and Antigen Presenting Cells (APC). He or she will use FACS analysis and various imaging techniques to investigate the above question.  \nPosition 2  \n\nGenerate and test mammalian cells edited by CRISPR technology.\nPerform various assays including western blotting\, qPCR\, ELISA\, FACS to determine changes in gene expression.\nOptimize culture conditions for primary cells and conduct in vitro phagocytosis assay.\n\nPosition 3 \nMetastases are the principal cause of death in patients with colorectal cancer (CRC). In order to develop effective methods for prevention and targeting of metastatic disease\, it is of crucial importance to better understand the cellular and molecular mechanisms regulating the metastatic cascade. The project will consist in evaluating the role of specific regulatory regions and signaling pathways in mediating the metastatic ability of colon cancer cells. First\, the intern will have to design\, clone and validate CRISPR-based tools (CRISPR KO or CRISPR i) to specifically and efficiently target genes and regulatory regions found in our in vivo screening and thought to be playing a key role in colon cancer cells metastatic ability. Also\, the intern will be involved in setting up a drug screening in order to assess the effect of different compounds on colon cancer cells in vitro. \nWho You Are  \nPosition 1  \n\nPreferred degree level: PhD\nPreferred majors are: Immunology\, Cell Biology.\nLab skills needed: FACS\, Immunofluorescence staining\, Cell Culture\, Fluorescence Microscopy\n\nPosition 2  \n\nPreferred degree level: BS\, MS\, or PhD\nMajors: Molecular Biology\, Cell Biology\, Immunology\nLab skills: mammalian cell culture\, cell transfection\, DNA/RNA preparation\, PCR\, FACS\n\nPosition 3  \n\nPreferred degree level: MS or PhD\nBackground in Molecular Biology\, Cell Biology\, Genetics\, Biochemistry\nPrevious experience with cell culture and molecular biology techniques (cloning\, digestion\, DNA preparation…) is highly desired\nPrevious experience with flow cytometry analysis and/or imaging techniques (confocal microscopy…) is preferred\nApplicants with good understanding of concepts in cancer biology/genomics/epigenetics will be prioritized
URL:https://ces.b2sg.org/event/genentech-19jan18/
LOCATION:Genentech\, 1 DNA Way\, South San Francisco\, CA\, 94080\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/genentech-logo.jpg
END:VEVENT
END:VCALENDAR